Date: 03-Sep-2020

Lupin Launches Generic Aravat Tablets In US Market To Treat Active RA

Pharma major Lupin Limited announced the launch of the United States Food and Drug Administration (FDA) approved leflunomide tablets USP, 10 mg and 20 mg

The product would be manufactured at Lupin’s Pithampur (Unit I) facility in India.

Leflunomide tablets USP, 10 mg and 20 mg, is the generic equivalent of Aravat tablets, 10 mg and 20 mg, of Sanofi-Aventis US LLC., and is indicated for the treatment of adults with active rheumatoid arthritis (RA).

Leflunomide tablets USP had an annual sales of approximately US$ 42 million in the US, according to IQVIA MAT June 2020.